Fortis Healthcare CFO Gagandeep Singh Bedi quits

NEW DELHI: Fortis Healthcare on Thursday said its Chief Financial Officer Gagandeep Singh Bedi has resigned citing personal reasons.

The Board of Directors of the company at its meeting held today have considered Bedi’s resignation from the services of the company, and accepted the same, with effect from September 30, 2018, Fortis Healthcare said in a filing to BSE.

The resignation is due to personal reasons, it added.

Shares of Fortis Healthcare today closed at Rs 148.70 per scrip on BSE, down 0.07 per cent from the previous close.

  • Related Posts

    Yashoda Medicity lifts Benchmark in Critical Care to New High

    With the introduction of North India’s first Advanced VitalGo Total Lift Bed Technology Ghaziabad/ New Delhi: In an ideal hospital, critical care is most paramount and it is also the…

    A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

    Healthy Heart is a Misnomer until underpinned by Regular Screening Bangaluru/ New Delhi: Of late, heart health has become kind of a veritable conundrum. We were never so unsure of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

    FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

    Haryana intensifies crackdown on spurious drugs, FDA records 16 arrests in 10 months

    Haryana intensifies crackdown on spurious drugs, FDA records 16 arrests in 10 months

    FSSAI Issues Prohibition Orders against FOLINEURO Syrup and Neuherbs TRUE VITAMIN over Misleading Claims

    FSSAI Issues Prohibition Orders against FOLINEURO Syrup and Neuherbs TRUE VITAMIN over Misleading Claims

    Pune Police Bust Illegal Bodybuilding Drug Racket, 5 Arrested; 50 Mephentermine Injections Seized In Major Crackdown

    Pune Police Bust Illegal Bodybuilding Drug Racket, 5 Arrested; 50 Mephentermine Injections Seized In Major Crackdown

    Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

    Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

    13 Years after Oxytocin Order, HC Seeks Compilance Status

    13 Years after Oxytocin Order, HC Seeks Compilance Status